SEC Filings

8-K
MEDTRONIC PLC filed this Form 8-K on 11/21/2017
Entire Document
 


MEDTRONIC PLC
WORLD WIDE REVENUE: GEOGRAPHIC(1) 
(Unaudited)
 
 
 
 
 
 
 
ADJUSTED
 
 
 
 
 
 
 
 
ADJUSTED
 
REPORTED
 
CONSTANT CURRENCY(2)
 
REVISED(3)
 
 
 
 
REPORTED
 
CONSTANT CURRENCY(2)
 
REVISED(3)
 
 
(in millions)
FY18
Q2
 
FY17
Q2
 
Reported
Growth
 
Currency Impact
 
FY18
Q2
 
FY17
Q2
 
Comparable Constant Currency Growth
 
 
FY18
Q2 YTD
 
FY17
Q2 YTD
 
Reported
Growth
 
Currency Impact
 
FY18
Q2 YTD
 
FY17
Q2 YTD
 
Constant Currency Growth
U.S.
$
1,423

 
$
1,353

 
5
 %
 
$

 
$
1,423

 
$
1,353

 
5
 %
 
 
$
2,756

 
$
2,650

 
4
 %
 
$

 
$
2,756

 
$
2,650

 
4
 %
Non-U.S. Developed
895

 
823

 
9

 
13

 
882

 
823

 
7

 
 
1,782

 
1,652

 
8

 
4

 
1,778

 
1,652

 
8

Emerging Markets
455

 
408

 
12

 
3

 
452

 
408

 
11

 
 
881

 
800

 
10

 

 
881

 
800

 
10

Cardiac & Vascular Group
2,773

 
2,584

 
7

 
16

 
2,757

 
2,584

 
7

 
 
5,419

 
5,102

 
6

 
4

 
5,415

 
5,102

 
6

 
 
 
 
 

 
 
 

 
 
 

 
 
 
 
 
 

 
 
 

 
 
 

U.S.
795

 
1,266

 
(37)
 

 
795

 
834

 
(5
)
 
 
2,040

 
2,501

 
(18)
 

 
2,040

 
2,069

 
(1
)
Non-U.S. Developed
783

 
853

 
(8)
 
5

 
778

 
754

 
3

 
 
1,648

 
1,716

 
(4)
 
(8
)
 
1,656

 
1,617

 
2

Emerging Markets
374

 
354

 
6
 
3

 
371

 
322

 
15

 
 
750

 
680

 
10
 
2

 
748

 
648

 
15

Minimally Invasive Therapies Group
1,952

 
2,473

 
(21)
 
8

 
1,944

 
1,910

 
2

 
 
4,438

 
4,897

 
(9)
 
(6
)
 
4,444

 
4,334

 
3

 
 
 
 
 

 
 
 

 
 
 

 
 
 
 
 
 

 
 
 

 
 
 

U.S.
1,258

 
1,261

 

 

 
1,258

 
1,261

 

 
 
2,479

 
2,468

 

 

 
2,479

 
2,468

 

Non-U.S. Developed
394

 
383

 
3

 
3

 
391

 
383

 
2

 
 
788

 
767

 
3

 
(2
)
 
790

 
767

 
3

Emerging Markets
211

 
182

 
16

 
1

 
210

 
182

 
15

 
 
405

 
363

 
12

 
(1
)
 
406

 
363

 
12

Restorative Therapies Group
1,863

 
1,826

 
2

 
4

 
1,859

 
1,826

 
2

 
 
3,672

 
3,598

 
2

 
(3
)
 
3,675

 
3,598

 
2

 
 
 
 
 

 
 
 

 
 
 

 
 
 
 
 
 

 
 
 

 
 
 

U.S.
258

 
272

 
(5
)
 

 
258

 
272

 
(5
)
 
 
501

 
535

 
(6
)
 

 
501

 
535

 
(6
)
Non-U.S. Developed
169

 
150

 
13

 
7

 
162

 
150

 
8

 
 
336

 
305

 
10

 
7

 
329

 
305

 
8

Emerging Markets
35

 
40

 
(13
)
 

 
35

 
40

 
(13
)
 
 
74

 
74

 

 

 
74

 
74

 

Diabetes Group
462

 
462

 

 
7

 
455

 
462

 
(2
)
 
 
911

 
914

 

 
7

 
904

 
914

 
(1
)
 
 
 
 
 

 
 
 

 
 
 

 
 
 
 
 
 

 
 
 

 
 
 

U.S.
3,734

 
4,152

 
(10
)
 

 
3,734

 
3,720

 

 
 
7,776

 
8,154

 
(5
)
 

 
7,776

 
7,722

 
1

Non-U.S. Developed
2,241

 
2,209

 
1

 
28

 
2,213

 
2,110

 
5

 
 
4,554

 
4,440

 
3

 
1

 
4,553

 
4,341

 
5

Emerging Markets
1,075

 
984

 
9

 
7

 
1,068

 
952

 
12

 
 
2,110

 
1,917

 
10

 
1

 
2,109

 
1,885

 
12

TOTAL
$
7,050

 
$
7,345

 
(4
)%
 
$
35

 
$
7,015

 
$
6,782

 
3
 %
 
 
$
14,440

 
$
14,511

 
 %
 
$
2

 
$
14,438

 
$
13,948

 
4
 %
See description of non-GAAP financial measures at the end of the earnings press release.

(1) U.S. includes the United States and U.S. territories. Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries of Western Europe. Emerging Markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as previously defined.
(2) Constant currency adjusted revenue, a non-GAAP financial measure, presents current period revenue using average exchange rates in effect during the applicable prior year period.
(3) Revised revenue excludes revenue related to the divested Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses for the second quarter of fiscal year 2017.

8

X